ACET MEXC RealStocks
Own real ACET shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-13 17:49:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Adicet Bio, Inc. (ACET) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.79, with a market capitalization of $27.43M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.74 to $11.20. This page covers its latest market performance, valuation, price trends and company information.
$27.43M | |
$2.92 | |
$3.00 | |
$2.74 | |
$2.93 | |
131.73K | |
232.32K | |
-- | |
$11.20 | |
$2.74 | |
-- | |
-- |
Adicet Bio, Inc. (ACET) is currently trading at $2.79 as of 2026-11-13 17:32:40, down 4.10% ($0.12) from the previous close of $2.93
During today's regular trading session, ACET has traded between $2.74 and $3.00, with a trading volume of 131.73K shares. The current price is near the lower end of today's range.
Over the past seven days, Adicet Bio, Inc. (ACET) moved from $3.10 to $2.79, representing a decline of 9.94% ($0.31).
The stock traded between $2.74 and $3.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 330.46 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.6%
ACET is currently trading at $2.79, placing it 0.6% of the way from its 52-week low of $2.74 to its 52-week high of $11.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 102 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Adicet Bio, Inc. (ACET) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ACET, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ACET shares and USD.
ACET Shares to USD
1.00 ACET shares = 2.792 USD
Calculations are estimates based on the latest available price and are for reference only.